Volume 21, Issue 1 (2018)                   mjms 2018, 21(1): 15-21 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mirzaee M, Haghighat S, Mahdavi M. Comparison of Immunization of Iran's Hepatitis B Vaccine, Vaccine Formulated in Montanide ISA 720 Aadjuvant and Fendrix Vaccine from GSK Company on the Balb/C Mice. mjms. 2018; 21 (1) :15-21
URL: http://mjms.modares.ac.ir/article-30-22435-en.html
1- Microbiology Department, Science & Technology Faculty, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
2- Recombinant Vaccines Research Center, Tehran University of Medical Sciences, Tehran, Iran
Abstract:   (7425 Views)
Aims: Vaccination is the only approach to prevent hepatitis B virus infection, But some people do not get a good immune response to the commercial hepatitis B vaccine. The purpose of the present study was to compare the immunization of Iran's Hepatitis B vaccine, vaccine formulated in montanide ISA 720 adjuvant and Fendrix vaccine from GSK company on the Balb/c mice.
Materials and Methods: In this experimental study, 54 female inbred Balb/c mice were injected in three different formulations of vaccine subcutaneously with two-week intervals. Quantitative amount of IFN-γ, IL-4, and IL-2 cytokines and the IFN-γ/IL-4 ratio from spleen cell culture Supernatant and the anti-HBs Ag antibody level After each injection withBlood sampling were evaluated by ELISA method. Data were analyzed by Graphpad prism 6.1 software via one way analysis of variance.
Findings: The vaccine recipient groups did not show significant differences in IFN-γ, IL-2 cytokines and IFN-γ/ IL-4 ratio (p>0.05). Iranian commercial vaccine significantly increased the cytokine IL-4 in comparison with the Fendrix and HBs-MON720 groups (p<0.05). Antibody responses after the first and second injection of Fendrix and HBs-MON720 showed a significant increase in comparison with the HBS-ALUM group (p<0.05), but no significant difference was observed after the third injection (p>0.05).
Conclusion: Cytokine responses in The Fendrix vaccine and HBs-MON720 vaccine are partly similar to the Iran's Hepatitis B vaccine but after two injections, Fendrix and HBs-MON720 vaccine showed a higher antibody response.
Full-Text [PDF 486 kb]   (858 Downloads)    
Article Type: Original Research | Subject: Biochemistry
Received: 2018/06/25 | Accepted: 2018/06/25

1. Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, et al. Virological response to ‎entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. ‎‎2013;62(5):760-5.‎ [Link]
2. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J ‎Gastrointestin Liver Dis. 2007;16(4):403-6.‎ [Link]
3. Madaliński K, Kołakowska A, Godzik P. Current views on the persistence of immunity following hepatitis B ‎vaccination. Przegl Epidemiol. 2015;69(1):47-51. [English-Polish]‎ [Link]
4. Zhang X, He P, Hu Z, Wang X, Liang Z. Enhanced specific immune responses by CpG DNA in mice ‎immunized with recombinant hepatitis B surface antigen and HB vaccine. Virol J. 2011;8:78.‎ [Link] [DOI:10.1186/1743-422X-8-78]
5. Van Loveren H, Van Amsterdam JG, Vandebriel RJ, Kimman TG, Rümke HC, Steerenberg PS, et al. Vaccine-‎induced antibody responses as parameters of the influence of endogenous and environmental factors. ‎Environ Health Perspect. 2001;109(8):757-64.‎ [Link]
6. Aiyer-Harini P, Ashok-Kumar HG, Kumar GP, Shivakumar N. An overview of immunologic adjuvants -A ‎review. J Vaccines Vaccin. 2013;4(1):1000167.‎ [Link]
7. Walayat S, Ahmed Z, Martin D, Puli S, Cashman M, Dhillon S. Recent advances in vaccination of non-‎responders to standard dose hepatitis B virus vaccine. World J Hepatol. 2015;7(24):2503-9.‎ [Link] [DOI:10.4254/wjh.v7.i24.2503]
8. Hoebe CJ, Vermeiren AP, Dukers-Muijrers NH. Revaccination with Fendrix® or HBVaxPro® results in ‎better response rates than does revaccination with three doses of Engerix-B‏® ‏in previous non-responders. ‎Vaccine. 2012;30(48):6734-7.‎ [Link] [DOI:10.1016/j.vaccine.2012.08.074]
9. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines. ‎‎2007;6(2):133-40.‎ [Link] [DOI:10.1586/14760584.6.2.133]
10. Lindemann M, Zaslavskaya M, Fiedler M, Wilde B, Heinemann FM, Heinold A, et al. Humoral and cellular ‎responses to a single dose of fendrix in renal transplant recipients with non-response to previous hepatitis B ‎vaccination. Scand J Immunol. 2017;85(1):51-7.‎ [Link]
11. Aghasadeghi M, Sadat S, Bahramali G, Hekmat S, Motevali F, Alizadeh S, et al. Evaluating novel adjuvant ‎systems for the induction of humeral and cellular immune responses in hepatitis C virus capsid protein ‎immunization. J Kashan Univ Med Sci (FEYZ). 2010;14(1):26-39. [Persian]‎ [Link]
12. Miles AP, McClellan HA, Rausch KM, Zhu D, Whitmore MD, Singh S, et al. Montanide ISA 720 vaccines: ‎Quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine ‎formulations. Vaccine. 2005;23(19):2530-9.‎ [Link]
13. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: A new generation of ‎water in oil emulsions as adjuvants for human vaccines. Expert Review Vaccines. 2002;1(1):111-8.‎ [Link] [DOI:10.1586/14760584.1.1.111]
14. Mata E, Salvador A, Igartua M, Hernández RM, Pedraz JL. Malaria vaccine adjuvants: Latest update and ‎challenges in preclinical and clinical research. BioMed Res Int. 2013. Available from: ‎https://www.hindawi.com/journals/bmri/2013/282913/.‎ [Link]
15. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, et al. Clinical characteristics of patients ‎infected with hepatitis B virus genotypes A, B, and C. J Gastroenterol. 2002;37(1):35-9.‎ [Link]
16. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type ‎antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior ‎protection. Vaccine. 2008;26(19):2350-9.‎ [Link] [DOI:10.1016/j.vaccine.2008.02.063]
17. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H. AS04, an aluminum salt- and ‎TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to ‎enhanced adaptive immunity. J Immunol. 2009;183(10):6186-97.‎ [Link] [DOI:10.4049/jimmunol.0901474]
18. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal ‎insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther. 2008;8(2):235-‎‎47.‎ [Link]
19. Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, Birkett A, et al. Safety and enhanced ‎immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant ‎Montanide ISA 720 in a phase I trial. Infect Immun. 2005;73(6):3587-97.‎ [Link]
20. Liu J, Chen P, Jiang Y, Wu L, Zeng X, Tian G, et al. A duck enteritis virus-vectored bivalent live vaccine ‎provides fast and complete protection against H5N1 avian influenza virus infection in ducks. J Virol. ‎‎2011;85(21):10989-98.‎ [Link]
21. Tong NKC, Beran J, Kee SA, Miguel JL, Sanchez C, Bayas JM et al. Immunogenicity and safety of an ‎adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005;68(5):2298-‎‎303.‎ [Link]
22. Saul A, Hensmann M, Sattabongkot J, Collins WE, Barnwell J, Langermans J. Immunogenicity in rhesus of ‎the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720. Parasite ‎Immunol. 2007;29(10):525-33.‎ [Link]